➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
McKesson
Baxter
Harvard Business School
McKinsey

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,504,647

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,504,647
Title:Pharmaceutical formulations of desmopressin
Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
Inventor(s): Nilsson; Anders (Lund, SE), Lindner; Hans (Berlin, DE), Wittendorff; Jorgen (Hvidovre, DK)
Assignee: FERRING B.V. (Hoofddorp, NL)
Application Number:14/947,261
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,504,647
Patent Claims: 1. A solid orodispersible pharmaceutical dosage form of desmopressin acetate, comprising desmopressin acetate in an open matrix network carrying the desmopressin acetate, wherein the open matrix network comprises a water-soluble or water-dispersible carrier material inert to the desmopressin acetate that comprises gelatin, and wherein the dosage form disintegrates in the mouth within 10 seconds.

2. The dosage form of clam 1, wherein the gelatin comprises fish gelatin.

3. The dosage form of claim 1, wherein the gelatin comprises non-gelling fish gelatin.

4. The dosage form of claim 1, obtained by a process comprising sublimation of solvent from a composition comprising desmopressin acetate and a solution of the gelatin carrier material in a solvent.

5. The dosage form of claim 4, wherein the sublimation is carried out by freeze-drying the composition comprising desmopressin acetate and a solution of the gelatin carrier material in a solvent.

6. The dosage form of claim 4, wherein the composition is subject to sublimation in a mold.

7. The dosage form of claim 4, wherein the solvent is water.

8. The dosage form of claim 4, wherein the solution has a pH of from 3to 6.

9. A blister pack comprising a solid orodispersible pharmaceutical dosage form of claim 1.

10. A process for preparing a solid orodispersible pharmaceutical dosage form of desmopressin acetate which disintegrates in the mouth within 10 seconds, comprising sublimating solvent from a composition comprising desmopressin acetate and a solution of a water-soluble or water-dispersible carrier material inert to the desmopressin acetate that comprises gelatin in a solvent.

11. The process of clam 10, wherein the gelatin comprises fish gelatin.

12. The dosage form of claim 10, wherein the gelatin comprises non-gelling fish gelatin.

13. The process of claim 10, wherein the subliming is carried out by freeze-drying a composition comprising desmopressin acetate and a solution of the gelatin carrier material in a solvent.

14. The process of claim 10, wherein the composition is subject to the subliming in a mold.

15. The process of claim 10, wherein the solvent is water.

16. The process of claim 10, wherein the pH of the solution is from 3 to 6.

17. A method of administering desmopressin acetate to a subject in need thereof, comprising administering the solid orodispersible pharmaceutical dosage form of claim 1 to the subject.

18. The method of clam 17, wherein the subject is in need of voiding postponement and/or the treatment of incontinence, primary nocturnal enuresis (PNE), nocturia, and/or central diabetes insipidus.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Medtronic
AstraZeneca
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.